Cargando…
Diagnosing Alzheimer’s Disease Specifically and Sensitively With pLG72 and Cystine/Glutamate Antiporter SLC7A11 AS Blood Biomarkers
BACKGROUND: Reliable blood biomarkers for Alzheimer’s disease (AD) have been lacking. The D-amino acids oxidase modulator (named pLG72) modulates glutamate N-methyl-D-aspartate receptor activity. The cystine/glutamate antiporter contains a SLC7A11 subunit, which mediates glutamate release. This stud...
Autores principales: | Lane, Hsien-Yuan, Lin, Chieh-Hsin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850657/ https://www.ncbi.nlm.nih.gov/pubmed/35986919 http://dx.doi.org/10.1093/ijnp/pyac053 |
Ejemplares similares
-
d-Amino Acids and pLG72 in Alzheimer’s Disease and Schizophrenia
por: Cheng, Yu-Jung, et al.
Publicado: (2021) -
pLG72 levels increase in early phase of Alzheimer’s disease but decrease in late phase
por: Lin, Chieh-Hsin, et al.
Publicado: (2019) -
Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment
por: Hung, Chung-Chieh, et al.
Publicado: (2021) -
The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer
por: Jyotsana, Nidhi, et al.
Publicado: (2022) -
Identification of pLG72-Induced Oxidative Stress Using Systemic Approaches
por: Wang, Maofeng, et al.
Publicado: (2015)